Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA
May 09, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 09, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
March 31, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 31, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing...
Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
March 07, 2017 07:45 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 07, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
March 03, 2017 07:44 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 03, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
February 17, 2017 07:45 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO):ABO-102 gene therapy well-tolerated in 4 subjects (N=3 low dose, N=1 high dose) through 650 days...
Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017
February 07, 2017 07:45 ET
|
Abeona Therapeutics Inc
Multiple Oral Platform Presentations and Poster Sessions Highlighting Gene Therapy Programs, Tuesday, February 14th through Thursday, February 16th NEW YORK and CLEVELAND, Feb. 07, 2017 (GLOBE...
Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A
February 01, 2017 07:43 ET
|
Abeona Therapeutics Inc
ABO-102, the leading clinical gene therapy program for Sanfilippo syndrome type A patients, has demonstrated central nervous system (CNS) and peripheral organ disease biopotencyFirst high dose cohort...